New program halts population weight gain in Colorado clinics

A novel weight management initiative called PATHWEIGH, developed by endocrinologist Leigh Perreault, has successfully stopped population-level weight gain in primary care settings across Colorado. Tested in a large-scale trial involving over 274,000 patients, the program increased access to obesity treatments and is now attracting interest from health systems nationwide. Published results show a 0.58 kg reduction in average weight gain over 18 months, marking a significant public health advancement.

Endocrinologist Leigh Perreault, a professor at the University of Colorado Anschutz School of Medicine who practices in Westminster, grew frustrated with standard weight management advice in primary care. Patients often left with generic recommendations to eat better and exercise more, despite ongoing issues like diabetes and hypertension. Perreault realized many medications treated symptoms rather than addressing obesity as the root cause. "None of these people want to be on these medications and I thought if I could just help them with their weight, many of these health concerns would probably go away," she said.

To tackle this, Perreault and colleagues created PATHWEIGH, a structured system funded by the National Institutes of Health. It rolled out across 56 UCHealth primary care clinics in Colorado, involving 274,182 patients in one of the largest randomized trials of its kind. The program features dedicated visits focused solely on weight care, triggered by patient requests at the front desk. This activates an electronic health record workflow, including a patient survey that streamlines clinician notes and emphasizes practical steps.

Results, published in Nature Medicine in 2025, revealed PATHWEIGH reduced average population weight gain by 0.58 kg over 18 months, reversing the typical upward trend. It boosted the likelihood of receiving weight-related care by 23%, with one in four eligible patients accessing services like lifestyle counseling. Prescriptions for anti-obesity medications doubled during the trial. "With PATHWEIGH, we showed that we absolutely eliminated population weight gain across all of our primary care, which has never been done previously," Perreault noted.

The approach customizes treatments, reduces awkward weight discussions, and builds a clear pathway for care, likened by Perreault to a "highway" for various weight loss options. While individual changes may seem modest, they hold substantial public health value against annual average gains of about 0.5 kg. The Obesity Association now recommends PATHWEIGH in its standards, and five health systems in seven states are exploring adoption. Perreault calls it a "home-grown" blueprint for advancing obesity care.

Verwandte Artikel

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
Bild generiert von KI

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Von KI berichtet Bild generiert von KI Fakten geprüft

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.

Von KI berichtet Fakten geprüft

An international meta-analysis slated for presentation at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (May 12–15) suggests that people who increase their walking to roughly 8,500 steps a day during a weight-loss program and sustain similar levels afterward may be less likely to regain weight.

A minimally invasive procedure called duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing drugs like Ozempic and tirzepatide. Early results from the REMAIN-1 clinical trial show treated participants regained far less weight than those in a control group after six months off medication. The findings are set for presentation at Digestive Disease Week 2026.

Von KI berichtet Fakten geprüft

University of Oklahoma scientists report that the hormone FGF21 reduces body weight in obese mice by acting on a hindbrain pathway—centered on the nucleus of the solitary tract and area postrema—that relays signals to the parabrachial nucleus. The team says the mechanism overlaps anatomically with brain regions implicated in GLP-1 drugs, but appears to promote weight loss mainly by increasing metabolic rate rather than primarily suppressing food intake.

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen